Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.

Sonoma Biotherapeutics, a US-headquartered immunotherapy developer, has raised $265m in a series B round featuring spinout-focused venture capital firm Osage University Partners. The round was led by private equity firm Ally Bridge Group and included Fidelity, ArrowMark Partners, Avidity Partners, Casdin Capital, Deep Track Capital, Frazier Healthcare Partners, Janus Henderson Investors and Mirae Asset. Piper…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.